Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tumor immune microenvironment and clinical outcomes in stage IV urothelial cancer: YODO study.

International journal of clinical oncology - 1 Oct 2023

Nishiyama Hiroyuki, Tsuzuki Toyonori, Ohyama Chikara, Matsuyama Hideyasu, Shinozaki Kenta, Hayashi Yuko, Hayashi Nobuya, Koto Ryo, Shin Eisei, Ogawa Osamu

Abstract excerpt

BACKGROUND: Bladder cancer is the 10th most common cancer globally, with a growing incidence in Japan. Evaluation of molecular, genetic, and cellular biomarkers that predict treatment response and prognosis in patients with metastatic urothelial carcinoma (mUC) may help optimize sequential treatment strategies with chemotherapy and immune checkpoint inhibitors (ICIs). METHODS: This multicenter, retrospective...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antineoplastic Agents, Immunological

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to B7-H1 Antigen

Share to Biomarkers, Tumor

Share to Carcinoma, Transitional Cell

Share to Lung Neoplasms

Share to Tumor Microenvironment

Share to Urinary Bladder Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 37498492
DOI: 10.1007/s10147-023-02386-y
PMCID: PMC10543076

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tumor immune microenvironment and clinical outcomes in stage IV urothelial cancer: YODO study.PMID 37498492Read ↗

Macrophage correlates with immunophenotype and predicts anti-PD-L1 response of urothelial cancer.Semantic proximity Read ↗

Multi-omics Perspective on the Tumor Microenvironment based on PD-L1 and CD8 T-Cell Infiltration in Urothelial CancerSemantic proximity Read ↗

An Immune-Related lncRNA Model for Predicting Prognosis, Immune Landscape and Chemotherapeutic Response in Bladder CancerSemantic proximity Read ↗

Risk stratification based on immune signature and prediction of immune checkpoint inhibitor’s efficacy for bladder urothelial carcinomaSemantic proximity Read ↗

Clinicopathological characteristics, molecular landscape, and biomarker landscape for predicting the efficacy of PD-1/PD-L1 inhibitors in Chinese population with mismatch repair deficient urothelial carcinoma: a real-world studySemantic proximity Read ↗

Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.Semantic proximity Read ↗

Identification of Four Immune Subtypes in Bladder Cancer Based on Immune Gene SetsSemantic proximity Read ↗

PD-L1 expression and its correlation with tumor biomarkers in Chinese urothelial bladder cancer.Semantic proximity Read ↗

Prognosis and immune landscape of bladder cancer can be predicted using a novel miRNA signature associated with cuproptosisSemantic proximity Read ↗

Development and validation a pyroptosis related gene prognostic index for metastatic urothelial carcinoma based on immune checkpoint blockade therapySemantic proximity Read ↗

Three Conserved Immune Dysfunction and Exclusion Subtypes in Bladder and Pan-cancers: Prognostic and Immunotherapeutic SignificanceSemantic proximity Read ↗

A comprehensive analysis of the significance of immunogenic cell death-related genes in the prognosis and immune microenvironment of patients with bladder cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.